Revvity (RVTY) Earnings Date & Reports

Key Takeaways

• Revvity reported third-quarter 2026 revenue of $728.9 million, up 4.3% year over year, with pro forma organic growth of 7%.
• Adjusted earnings per share (EPS) rose roughly 17% to $1.38, beating consensus estimates near $1.30.
• The Life Sciences segment led results with 9% organic growth, fueled by improving pharmaceutical and biotech demand.
• Diagnostics grew 5% organically on a pro forma basis, excluding the China immunodiagnostics business slated for divestiture.
• Management raised full-year 2026 adjusted EPS guidance to a range of $5.40 to $5.45 and lifted its revenue outlook to about $2.86 billion.
• For additional context, explore Revvity's Major News, Today's Price Move, Price Targets, and Forecast pages.
• Discover Trending AI Robots to explore AI-driven trading strategies and market opportunities.

Earnings Context and Why It Matters

Revvity is a global life sciences and diagnostics company formed in 2023 following the rebranding of PerkinElmer. Its quarterly earnings serve as a barometer for two important end markets: pharmaceutical and biotech research spending, and specialty clinical diagnostics. After several quarters shaped by soft academic demand and pronounced China headwinds, this report was closely watched for signs of a genuine recovery in customer funding. Investors were also monitoring how the company's push into AI-enabled software and a planned exit from its China immunodiagnostics business would reshape growth and margins. Strong life sciences momentum and an upgraded full-year outlook signal that the company's transformation strategy is beginning to translate into financial results.

Reported Results

For the third quarter of fiscal 2026, Revvity reported revenue of $728.9 million, an increase of 4.3% from the prior-year period and ahead of consensus estimates near $695 million. On a pro forma basis, which adjusts for the pending divestiture of the China immunodiagnostics business, revenue was $709.6 million, up 7.4%, with organic growth of 7%.

Adjusted EPS from continuing operations came in at $1.38, up about 17% from $1.18 a year ago and above the consensus estimate of roughly $1.30. On a generally accepted accounting principles (GAAP) basis, EPS from continuing operations was $0.56, compared with $0.41 in the year-ago quarter.

By segment, Life Sciences revenue rose 10.7% to $379.6 million, with 9% organic growth driven by improving pharma, biotech, and academic demand. Diagnostics revenue declined 1.9% on a reported basis to $349.3 million, but grew 4% on a pro forma basis and 5% organically once the China immunodiagnostics business was excluded. Adjusted operating margin expanded to 28.7%, or 29.4% on a pro forma basis, reflecting higher volumes and operational efficiency.

Management raised its full-year 2026 outlook to adjusted EPS of $5.40 to $5.45, up from $5.30 to $5.40, with revenue of about $2.86 billion and roughly 5% pro forma organic growth.

AI Screener

Tickeron's AI Screener is an AI-powered stock and exchange-traded fund (ETF) discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to surface trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening, making it a practical resource for earnings-focused research. Explore the AI Screener to help identify setups aligned with your own strategy.

Market Reaction and Investor Sentiment

Investors responded enthusiastically to the results, sending Revvity shares sharply higher intraday and toward a fresh 52-week high. The market's positive reaction reflected the combination of a top-and-bottom-line beat, broad-based organic growth, and an upward revision to full-year guidance. Sentiment was further supported by evidence that pharmaceutical and biotech spending is normalizing and that AI-related demand is broadening beyond the company's high-content screening franchise. The decision to divest the China immunodiagnostics business was also viewed favorably, as it reduces exposure to a persistently weak end market while improving the reported margin profile over time.

Forward Outlook and Key Factors to Monitor

Revvity's upgraded 2026 guidance signals confidence that its growth and efficiency initiatives are taking hold, but several factors will shape the path ahead. Management noted that fourth-quarter growth may moderate somewhat, partly because some reagent bulk orders shifted into the third quarter and Signals Software growth is expected to ease from high-teens into the mid-teens range.

Investors will want to track the timing and execution of the planned China immunodiagnostics divestiture, which is subject to regulatory approvals and customary closing conditions. The completion of that transaction would simplify the company's reporting structure and lift its blended margin profile. Sustained recovery in pharmaceutical, biotech, and academic funding remains a central driver, as does the trajectory of AI-enabled product adoption across the portfolio.

On the diagnostics side, reproductive health demand and the rollout of the company's type 1 diabetes screening assay in Europe are worth monitoring, even as weak Chinese birth rates continue to weigh on that franchise. Margin expansion, free cash flow generation, and the pace of capital deployment will also remain important indicators of how effectively management converts improving demand into durable earnings growth.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations